Circio Holding ASA (0RIS.L)

11.20 +0.08 (+0.69%) As of 04:10PM BST. Market open.

Circio Holding ASA

Vollsveien 19
Lysaker 1366
Norway
47 21 39 88 10
https://www.circio.com

Sector(s): 
Industry: 
Full-time employees: 9

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Lubor Gaal Ph.D.	Chief Financial Officer	2.88M	N/A	1968
Mr. Ola Melin	Chief Operating Officer	1.97M	N/A	N/A
Dr. Thomas Birkballe Hansen	Chief Technology Officer	1.97M	N/A	N/A
Dr. Victor Levitsky M.D., Ph.D.	Chief Scientific Officer	790k	N/A	N/A
Mr. Jon Amund Eriksen M.Sc., MSc	Special Advisor	1.86M	N/A	N/A
Prof. Gustav Gaudernack Ph.D.	Chief Scientific Adviser	N/A	N/A	N/A
Dr. Peter Skorpil Ph.D.	Vice President of Business Development	1.07M	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.

Description

Circio Holding ASA, a clinical stage cancer immunotherapy and RNA therapeutics company. Its lead product candidate is ONCOS-102 for the treatment of mesothelioma and melanoma cancer. The company is also developing TG-01, a cancer vaccine program based on neoantigen vaccine for mutant KRAS cancers; and ONCOS immunotherapy technologies to stimulate the immune system. The company has collaboration agreement with the University of Kansas Cancer Center, as well as a research collaboration with Neoregen Biotech to develop novel NICT-delivered circVec therapeutic candidates. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023. Circio Holding ASA was incorporated in 2010 and is based in Lysaker, Norway.

Corporate governance

Circio Holding ASA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.